Unavailability of safer anti-arrhythmic drugs is expected to be major issue in the atrial fibrillation market, according to a new report from GlobalData.

Titled ‘PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025‘, the report states that the existing drugs targeting the restoration and maintenance of sinus rhythm have low safety and efficacy.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The most popular generic anti-arrhythmic drug, amiodarone, for example, is effective in heart rhythm control but has a number of side effects including proarrhythmia, along with thyroid, liver, skin, and pulmonary complications.

The unmet need for safer antiarrhythmic drugs is compounded by the low level of drug development activity in the atrial fibrillation market. There are currently no new drugs in late-stage development, according to GlobaData’s Senior Analyst, Jesus Cuaron, Ph.D, PPM.

“The development of two promising drugs, namely Gilead’s fixed-dose combination of ranolazine / dronedarone and Laguna Pharmaceuticals’ vanoxerine, was recently discontinued.”

The development of two promising drugs, namely Gilead’s fixed-dose combination of ranolazine / dronedarone and Laguna Pharmaceuticals’ vanoxerine, was recently discontinued.

Just three drugs in Phase II and one drug in Phase I are currently in development, a major reason for this being the high risk of drug development, Jesus Cuaron opines. Large and costly clinical trials need to be undertaken to establish the safety and efficacy of an anti-arrhythmic drug.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, anti-arrhythmic market is dominated by genericised drugs with more expected to be added in the future, which will lead to a rapid decline in market value from 2022, the report adds.

Anti-arrhythmic drugs are also expected to face difficulties in securing reimbursement and addition to hospital formularies due to cost constraints faced by national health authorities and the availability of cheaper generic alternatives.

Future drug development in the atrial fibrillation market is expected to move towards the use of procedural technologies, such as catheter ablation, for rhythm control.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact